Supernus outlines $840M-$870M 2026 revenue target as ONAPGO supply normalizes and growth brands accelerate
Source: SeekingAlpha
2026-02-25 04:28:48 ET
More on Supernus Pharmaceuticals
- Supernus: Outlook For 2026 Positive, Upholding Buy Rating
- Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
- Supernus Pharmaceuticals GAAP EPS of $0.07 beats by $0.28, revenue of $211.6M beats by $16.44M
- Supernus Pharmaceuticals Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Supernus outlines $840M–$870M 2026 revenue target as ONAPGO supply normalizes and growth brands accelerate
Supernus Pharmaceuticals Inc.
NASDAQ: SUPN
SUPN Trading
3.77% G/L:
$55.04 Last:
229,766 Volume:
$54.29 Open:
SUPN Latest News
February 26, 2026 09:35:00 am
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments
February 24, 2026 04:05:00 pm
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
SUPN Stock Data
$2,924,306,850
52,293,487
2.13%
131
N/A
Pharmaceuticals
Healthcare
US
Rockville
